The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Differentiated pharmacokinetic and pharmacodynamic properties of a highly selective MET kinase inhibitor, OMO-1: Implications for efficacy and safety.
 
Timothy Pietro Suren Perera
Employment - Octimet
Leadership - Octimet
Stock and Other Ownership Interests - Octimet
Consulting or Advisory Role - Octimet
Research Funding - Octimet
Patents, Royalties, Other Intellectual Property - Patent Holder
 
Marion Libouban
Employment - Octimet
 
Ellen Jansen
Employment - Galapagos NV; Octimet
 
Marc Tjwa
Employment - Octimet
 
Eric Ciamporcero
Employment - Octimet
 
Ann Meulemans
Employment - Octimet
Leadership - Octimet
Stock and Other Ownership Interests - Octimet
 
Annegret Van der Aa
Employment - Galapagos NV; Octimet
Leadership - Octimet
Stock and Other Ownership Interests - Galapagos NV
 
Glen Clack
Employment - Carrick Therapeutics; Octimet
Stock and Other Ownership Interests - Carrick Therapeutics; Octimet
Consulting or Advisory Role - Aptus Clinical; inventiva pharma; MorEx; PCI Biotech; Redx Pharma
 
Martijn P. Lolkema
Consulting or Advisory Role - Incyte; Johnson & Johnson; Novartis; Sanofi
Research Funding - Astellas Pharma (Inst); Johnson & Johnson (Inst); Merck Sharp & Dohme (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Merck Sharp & Dohme